Home›Trial›NCT07562087
NCT07562087Phase 2RECRUITING

A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure

Study Summary

This study is designed to evaluate the safety, tolerability, and pharmacokinetics of TP05 administered orally to healthy adult participants.

Conditions
Lyme Disease
Interventions / Drugs
TP-05 (lotilaner) Low DoseTP-05 (lotilaner) High DosePlacebo
View on ClinicalTrials.gov ↗
Sponsor
TARS
Tarsus Pharmaceuticals, Inc.
Biotech / Pharma
C52/100
Study Details
Enrollment700 participants
Primary Completion—
Lead SponsorTarsus Pharmaceuticals, Inc.
Data Retrieved2026-06-17 02:58:25.715387+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 2 trials begin testing efficacy in a larger patient group (100–300). This is often where biotech binary events occur — positive Phase 2 data can significantly advance a company's pipeline narrative, while failures can be terminal for a program.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 700 participants
Sponsor Catalyst Profile

Tarsus Pharmaceuticals, Inc. (TARS) is the sponsoring company for this trial. BiotechSign currently grades this company C (52/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

TARS Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.